Asset overview
Program snapshot
Target: CD19
Cell type: NK_CELL
Indications: Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia
Sponsor: Xuzhou Medical University
Institution: Xuzhou Medical University
Car Nk
allogenic CD19-CAR-NK cells
allogenic CD19-CAR-NK cells is flagged as a low confidence because it has an active early-phase oncology cell-therapy trial at Xuzhou Medical University, with a unlinked patent signal linked through public patent-search heuristics. Manual review is still required.
Clinical evidence
Trial footprint
Phase: Early Phase1
Status: Unknown
Trial count: 1
Active trials: 0
First posted: February 22, 2023
Last updated: February 22, 2023
Signal summary
IP and BD posture
IP signal: Unlinked
BD label: Low Confidence
Confidence: Low
Manual review required: Yes
Scores
Deterministic scoring
Clinical translation0
IP linkage0
Licensing clarity3
Strategic interest3
Source
Public trial record
Review the underlying ClinicalTrials.gov record and treat Treelip output as a prioritization layer, not a final diligence conclusion.
NCT IDs: NCT05739227